BIM-23056 TFA, with the CAS number 1426173-61-6, is a chemical compound that belongs to a class of substances known for their potential therapeutic applications, particularly in the field of oncology. It is characterized by its specific molecular structure, which includes functional groups that contribute to its biological activity. The compound is typically presented as a trifluoroacetic acid (TFA) salt, which enhances its solubility and stability in various solvents, making it suitable for pharmaceutical formulations. BIM-23056 TFA has been studied for its mechanism of action, often involving the modulation of specific signaling pathways that are crucial for cancer cell proliferation and survival. Its efficacy and safety profile are evaluated through preclinical and clinical studies, focusing on its potential as a targeted therapy. As with many investigational compounds, detailed information regarding its pharmacokinetics, toxicity, and therapeutic index is essential for understanding its role in treatment regimens.

BIM-23056 TFA

1426173-61-6: BIM-23056 TFA, with the CAS number 1426173-61-6, is a chemical compound that belongs to a class of substances known for their potential therapeutic applications, particularly in the field of oncology. It is characterized by its specific molecular structure, which includes functional groups that contribute to its biological activity. The compound is typically presented as a trifluoroacetic acid (TFA) salt, which enhances its solubility and stability in various solvents, making it suitable for pharmaceutical formulations. BIM-23056 TFA has been studied for its mechanism of action, often involving the modulation of specific signaling pathways that are crucial for cancer cell proliferation and survival. Its efficacy and safety profile are evaluated through preclinical and clinical studies, focusing on its potential as a targeted therapy. As with many investigational compounds, detailed information regarding its pharmacokinetics, toxicity, and therapeutic index is essential for understanding its role in treatment regimens.

<p>BIM 23056 is a type of drug that binds to the receptor and inhibits its activity. BIM 23056 has been shown to have anticancer effects in vitro and in vivo. It is a membrane-permeable substance, which means it can pass through the cell membrane and into the cell where it blocks the function of certain receptors. This drug also has a physiological effect on mammalian tissue, including fibroblasts, as well as on other cells that are sensitive to growth factors.</p>

BIM 23056 trifluoroacetate

BIM 23056 TFA, a potent linear octapeptide antagonist of sst3 and sst5 somatostatin receptors, exhibits inhibition constants (K_i) of 10.8 for sst3 and 5.7 for

CAS 1426173-61-6

BIM-23056 TFA

BIM 23056 trifluoroacetate

Ref: 3D-AGA15561

BIM-23056 TFA

Ref: TM-T75844